GeoVax Labs (NASDAQ:GOVX – Get Rating) is one of 939 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare GeoVax Labs to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, valuation, risk, earnings and profitability.
Institutional & Insider Ownership
6.5% of GeoVax Labs shares are held by institutional investors. Comparatively, 45.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 8.3% of GeoVax Labs shares are held by company insiders. Comparatively, 14.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares GeoVax Labs and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|GeoVax Labs||$390,000.00||-$18.57 million||-0.22|
|GeoVax Labs Competitors||$1.86 billion||$251.86 million||-1.74|
GeoVax Labs’ rivals have higher revenue and earnings than GeoVax Labs. GeoVax Labs is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations and price targets for GeoVax Labs and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|GeoVax Labs Competitors||6363||20966||43185||867||2.54|
GeoVax Labs presently has a consensus target price of $10.00, indicating a potential upside of 1,392.54%. As a group, “Pharmaceutical preparations” companies have a potential upside of 137.49%. Given GeoVax Labs’ stronger consensus rating and higher possible upside, research analysts plainly believe GeoVax Labs is more favorable than its rivals.
Volatility and Risk
GeoVax Labs has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500. Comparatively, GeoVax Labs’ rivals have a beta of 1.12, indicating that their average share price is 12% more volatile than the S&P 500.
This table compares GeoVax Labs and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|GeoVax Labs Competitors||-3,155.99%||-170.93%||-7.51%|
GeoVax Labs rivals beat GeoVax Labs on 7 of the 13 factors compared.
About GeoVax Labs (Get Rating)
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.